HIV/AIDS VACCINE DEVELOPED AT THE UNIVERSITY OF WESTERN ONTARIO PROCEEDING TO HUMAN CLINICAL TRIALS

摘要

The first and only preventative HIV vaccine based on a genetically modified killed whole virus has received approval by the United States Food and Drug Administration (FDA) to start human clinical trials.Developed by Dr. Chil-Yong Kang and his team at The University of Western Ontario, with the support of Sumagen Canada, the vaccine (SAV001) holds tremendous promise, having already proven to stimulate strong immune responses in preliminary toxicology tests with no adverse effects or safety risks. It is the only HIV vaccine currently under development in Canada, andone of only a few in the world.